biostudies-literatureZheng XBeijing Xisike Clinical Oncology Research FoundationNational Natural Science Foundation of Chinae493https://www.ebi.ac.uk/biostudies/studies/S-EPMC10924640biostudies-literatureUnknown5(3)Treatment response and prognosis estimation in advanced pulmonary adenocarcinoma are challenged by the significant heterogeneity of the disease. The current Response Evaluation Criteria in Solid Tumors (RECIST) criteria, despite providing a basis for solid tumor response evaluation, do not fully encompass this heterogeneity. To better represent these nuances, we introduce the intertumoral heterogeneity response score (THRscore), a measure built upon and expanding the RECIST criteria. This retrospective study included patients with 3-10 measurable advanced lung adenocarcinoma lesions who underwent first-line chemotherapy or targeted therapy. The THRscore, derived from the coefficient of variation in size for each measurable tumor before and 4-6 weeks posttreatment, unveiled a correlation wiMedCommA novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score.PMC1092464082072565Y‐2019AZZD‐038682372954Miao QJiang KPeng WLin XZhang LWang HDing JTang GZhang QZou ZWu SKang MBai JChen XChen SZheng XYan JLi CMok TSKXiao WLi YZhong QLin GLu TCai YYang SXu YfalseA novel approach to evaluation of tumor response for advanced pulmonary adenocarcinoma using the intertumoral heterogeneity response score.Treatment response and prognosis estimation in advanced pulmonary adenocarcinoma are challenged by the significant heterogeneity of the disease. The current Response Evaluation Criteria in Solid Tumors (RECIST) criteria, despite providing a basis for solid tumor response evaluation, do not fully encompass this heterogeneity. To better represent these nuances, we introduce the intertumoral heterogeneity response score (THRscore), a measure built upon and expanding the RECIST criteria. This retrospective study included patients with 3-10 measurable advanced lung adenocarcinoma lesions who underwent first-line chemotherapy or targeted therapy. The THRscore, derived from the coefficient of variation in size for each measurable tumor before and 4-6 weeks posttreatment, unveiled a correlation wi2024-01-01T00:00:00Z2024 Mar2026-07-15T23:15:44.459Z2025-04-04T12:59:12.442ZS-EPMC109246403846339610.1002/mco2.493